Capricor Therapeutics (NASDAQ:CAPR) Announces Earnings Results

Capricor Therapeutics (NASDAQ:CAPR) issued its earnings results on Thursday, March 28th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04, reports. The business had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.23 million. Capricor Therapeutics had a negative return on equity of 191.49% and a negative net margin of 909.76%.

NASDAQ:CAPR traded down $0.01 during mid-day trading on Friday, hitting $0.53. The company had a trading volume of 119,620 shares, compared to its average volume of 313,352. Capricor Therapeutics has a 1 year low of $0.31 and a 1 year high of $1.58. The firm has a market capitalization of $17.82 million, a PE ratio of -1.02 and a beta of 1.47.

Several research analysts recently weighed in on the company. Zacks Investment Research raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 21st. ValuEngine raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. HC Wainwright cut their target price on Capricor Therapeutics from $8.60 to $3.50 and set a “buy” rating on the stock in a research report on Monday, December 31st. Finally, Maxim Group reaffirmed a “hold” rating on shares of Capricor Therapeutics in a research report on Wednesday, February 6th. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $3.75.

TRADEMARK VIOLATION NOTICE: This report was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also: Cost of equity and a company’s balance sheet

Earnings History for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.